1
|
Li P, Wu Y, Xie Y, Chen F, Chen SS, Li YH, Lu QQ, Li J, Li YW, Pei DX, Chen YJ, Chen H, Li Y, Wang W, Wang H, Yu HT, Ba Z, Cheng D, Ning LP, Luo CL, Qin XS, Zhang J, Wu N, Xie HJ, Pan JH, Shui J, Wang J, Yang JP, Liu XH, Xu FX, Yang L, Hu LY, Zhang Q, Li B, Liu QL, Zhang M, Shen SJ, Jiang MM, Wu Y, Hu JW, Liu SQ, Gu DY, Xie XB. [HbA1c comparison and diagnostic efficacy analysis of multi center different glycosylated hemoglobin detection systems]. Zhonghua Yu Fang Yi Xue Za Zhi 2023; 57:1047-1058. [PMID: 37482740 DOI: 10.3760/cma.j.cn112150-20221221-01220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 07/25/2023]
Abstract
Objective: Compare and analyze the results of the domestic Lanyi AH600 glycated hemoglobin analyzer and other different detection systems to understand the comparability of the detection results of different detectors, and establish the best cut point of Lanyi AH600 determination of haemoglobin A1c (HbA1c) in the diagnosis of diabetes. Methods: Multi center cohort study was adopted. The clinical laboratory departments of 18 medical institutions independently collected test samples from their respective hospitals from March to April 2022, and independently completed comparative analysis of the evaluated instrument (Lanyi AH600) and the reference instrument HbA1c. The reference instruments include four different brands of glycosylated hemoglobin meters, including Arkray, Bio-Rad, DOSOH, and Huizhong. Scatter plot was used to calculate the correlation between the results of different detection systems, and the regression equation was calculated. The consistency analysis between the results of different detection systems was evaluated by Bland Altman method. Consistency judgment principles: (1) When the 95% limits of agreement (95% LoA) of the measurement difference was within 0.4% HbA1c and the measurement score was≥80 points, the comparison consistency was good; (2) When the measurement difference of 95% LoA exceeded 0.4% HbA1c, and the measurement score was≥80 points, the comparison consistency was relatively good; (3) The measurement score was less than 80 points, the comparison consistency was poor. The difference between the results of different detection systems was tested by paired sample T test or Wilcoxon paired sign rank sum test; The best cut-off point of diabetes was analyzed by receiver operating characteristic curve (ROC). Results: The correlation coefficient R2 of results between Lanyi AH600 and the reference instrument in 16 hospitals is≥0.99; The Bland Altman consistency analysis showed that the difference of 95% LoA in Nanjing Maternity and Child Health Care Hospital in Jiangsu Province (reference instrument: Arkray HA8180) was -0.486%-0.325%, and the measurement score was 94.6 points (473/500); The difference of 95% LoA in the Tibetan Traditional Medical Hospital of TAR (reference instrument: Bio-Rad Variant II) was -0.727%-0.612%, and the measurement score was 89.8 points; The difference of 95% LoA in the People's Hospital of Chongqing Liang Jiang New Area (reference instrument: Huizhong MQ-2000PT) was -0.231%-0.461%, and the measurement score was 96.6 points; The difference of 95% LoA in the Taihe Hospital of traditional Chinese Medicine in Anhui Province (reference instrument: Huizhong MQ-2000PT) was -0.469%-0.479%, and the measurement score was 91.9 points. The other 14 hospitals, Lanyi AH600, were compared with 4 reference instrument brands, the difference of 95% LoA was less than 0.4% HbA1c, and the scores were all greater than 95 points. The results of paired sample T test or Wilcoxon paired sign rank sum test showed that there was no statistically significant difference between Lanyi AH600 and the reference instrument Arkray HA8180 (Z=1.665,P=0.096), with no statistical difference. The mean difference between the measured values of the two instruments was 0.004%. The comparison data of Lanyi AH600 and the reference instrument of all other institutions had significant differences (all P<0.001), however, it was necessary to consider whether it was within the clinical acceptable range in combination with the results of the Bland-Altman consistency analysis. The ROC curve of HbA1c detected by Lanyi AH600 in 985 patients with diabetes and 3 423 patients with non-diabetes was analyzed, the area under curve (AUC) was 0.877, the standard error was 0.007, and the 95% confidence interval 95%CI was (0.864, 0.891), which was statistically significant (P<0.001). The maximum value of Youden index was 0.634, and the corresponding HbA1c cut point was 6.235%. The sensitivity and specificity of diabetes diagnosis were 76.2% and 87.2%, respectively. Conclusion: Among the hospitals and instruments currently included in this study, among these four hospitals included Nanjing Maternity and Child Health Care Hospital in Jiangsu Province (reference instrument: Arkray HA8180), Tibetan Traditional Medical Hospital of TAR (reference instrument: Bio-Rad Variant Ⅱ), the People's Hospital of Chongqing Liang Jiang New Area (reference instrument: Huizhong MQ-2000PT), and the Taihe Hospital of traditional Chinese Medicine in Anhui Province (reference instrument: Huizhong MQ-2000PT), the comparison between Lanyi AH600 and the reference instruments showed relatively good consistency, while the other 14 hospitals involved four different brands of reference instruments: Arkray, Bio-Rad, DOSOH, and Huizhong, Lanyi AH600 had good consistency with its comparison. The best cut point of the domestic Lanyi AH600 for detecting HbA1c in the diagnosis of diabetes is 6.235%.
Collapse
Affiliation(s)
- P Li
- Department of Medical Laboratory and Pathology Center, the First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha 410007, China
| | - Y Wu
- Changsha DIAN Medical Laboratory, Changsha 410000, China
| | - Y Xie
- Changsha DIAN Medical Laboratory, Changsha 410000, China
| | - F Chen
- Department of Medical Laboratory and Pathology Center, the First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha 410007, China
| | - S S Chen
- Department of Medical Laboratory and Pathology Center, the First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha 410007, China
| | - Y H Li
- Department of Medical Laboratory and Pathology Center, the First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha 410007, China
| | - Q Q Lu
- Department of Medical Laboratory and Pathology Center, the First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha 410007, China
| | - J Li
- Department of Medical Laboratory and Pathology Center, the First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha 410007, China
| | - Y W Li
- Department of Laboratory Medicine, Henan Province Hospital of Traditional Chinese Medicine, Zhengzhou 450002, China
| | - D X Pei
- Department of Laboratory Medicine, Henan Province Hospital of Traditional Chinese Medicine, Zhengzhou 450002, China
| | - Y J Chen
- Department of Medical Laboratory, Nanjing Maternity and Child Health Care Hospital, Nanjing 210004, China
| | - H Chen
- Department of Clinical Laboratory, the Third Xiangya Hospital of Central South University, Changsha 410013, China
| | - Y Li
- Department of Medical Laboratory, the First Affiliated Hospital of Shandong First Medical University, Jinan 250014,China
| | - W Wang
- Department of Laboratory Medicine, Dongguan Chang'an Hospital, Dongguan 523843, China
| | - H Wang
- Department of Laboratory, Tongde Hospital of Zhejiang Province, Hangzhou 310012, China
| | - H T Yu
- Department of Laboratory, Tongde Hospital of Zhejiang Province, Hangzhou 310012, China
| | - Z Ba
- Clinical Laboratory, Tibetan Hospital of Tibet Atonomous Region, Lhasa 850002, China
| | - D Cheng
- Clinical Laboratory, Tibetan Hospital of Tibet Atonomous Region, Lhasa 850002, China
| | - L P Ning
- Department of Clinical Laboratory, the People's Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, China
| | - C L Luo
- Department of Clinical Laboratory, the People's Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, China
| | - X S Qin
- Department of Clinical Laboratory, Shengjing hospital of China Medical University, Shenyang 110004, China
| | - J Zhang
- Department of Clinical Laboratory, Shengjing hospital of China Medical University, Shenyang 110004, China
| | - N Wu
- Department of Medical Laboratory, Hengyang First People's Hospital, Hengyang 421002, China
| | - H J Xie
- Department of Medical Laboratory, Hengyang First People's Hospital, Hengyang 421002, China
| | - J H Pan
- Department of Medical Laboratory, the Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha 410004, China
| | - J Shui
- Department of Medical Laboratory, the Affiliated Changsha Central Hospital, Hengyang Medical School, University of South China, Changsha 410004, China
| | - J Wang
- Department of Medical Laboratory, the Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang 330006, China
| | - J P Yang
- Department of Medical Laboratory, the Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang 330006, China
| | - X H Liu
- Department of Clinical Laboratory, Gongli Hospital of Shanghai Pudong New Area, Shanghai 200135, China
| | - F X Xu
- Department of Clinical Laboratory, Gongli Hospital of Shanghai Pudong New Area, Shanghai 200135, China
| | - L Yang
- Department of Medical Laboratory, the People's Hospital of Chongqing Liang Jiang New Area, Chongqing 401121, China
| | - L Y Hu
- Department of Medical Laboratory, the People's Hospital of Chongqing Liang Jiang New Area, Chongqing 401121, China
| | - Q Zhang
- Department of Medical Laboratory, Taihe Hospital of traditional Chinese Medicine, Taihe County 236600, China
| | - B Li
- Department of Medical Laboratory, Taihe Hospital of traditional Chinese Medicine, Taihe County 236600, China
| | - Q L Liu
- Department of Clinical Laboratory, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, China
| | - M Zhang
- Department of Clinical Laboratory, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, China
| | - S J Shen
- Department of Medical Laboratory, the First People's Hospitao of Jiashan County, Zhejiang Province, Jiashan County 314100, China
| | - M M Jiang
- Department of Medical Laboratory, the First People's Hospitao of Jiashan County, Zhejiang Province, Jiashan County 314100, China
| | - Y Wu
- Department of Clinical Laboratory, the Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha 410005, China
| | - J W Hu
- Department of Clinical Laboratory, the Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha 410005, China
| | - S Q Liu
- Department of Clinical Laboratory Medicine, the First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang 421002, China
| | - D Y Gu
- Department of Laboratory Medicine, Shenzhen Second People's Hospital, Shenzhen 518025, China
| | - X B Xie
- Department of Medical Laboratory and Pathology Center, the First Affiliated Hospital of Hunan University of Chinese Medicine, Changsha 410007, China
| |
Collapse
|
2
|
Xia T, Ji Y, Lu YN, Xie HJ, You YW, You B. [Autophagy promotes recurrence of nasopharyngeal carcinoma via inducing the formation of dormant polyploid giant cancer cells]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2022; 57:1102-1109. [PMID: 36177565 DOI: 10.3760/cma.j.cn115330-20220119-00034] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
Objective: To explore the effect of dormant polyploid giant cancer cells (PGCC) on nasopharyngeal carcinoma (NPC) recurrence and to clarify the role of inhibition of autophagy in inhibiting NPC-PGCC formation and preventing NPC recurrence. Methods: NPC cells-derived PGCC (NPC-PGCC) were induced by paclitaxel (PTX), and the morphology, polyploid characteristics and cell activity of PGCC were identified by light microscopy, immunofluorescence and Live/Dead cell double staining assays. RNA-seq was used to analyze the differentially expressed genes between NPC-PGCC and diploid nasopharyngeal carcinoma cells CNE2. Functional enrichment and pathway annotation analysis of differentially expressed genes were performed using Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG). The level of autophagy in NPC-PGCC cells was assessed by Western Blot and transmission electron microscopy analysis. The role of autophagy in the formation of NPC-PGCC and the effect of NPC-PGCC on the recurrence of nasopharyngeal carcinoma were studied using a highly clinically relevant mouse nasopharyngeal carcinoma recurrence model. Statistical analysis was performed using GraphPad Prism 6 and P-values<0.05 were considered statistically significant. Results: NPC-PGCC induced by paclitaxel had the characteristics of burst-like division after dormancy. GO enrichment and KEGG pathway analyses identified the significant biological processes and pathways mainly concentrated in autophagy and related pathways involving the differentially expressed genes between NPC-PGCC and diploid nasopharyngeal carcinoma cells CNE2. The autophagy level was significantly enhanced in NPC-PGCC cells. In a highly clinically relevant mouse nasopharyngeal carcinoma recurrence model, the number of PGCC in the primary tumor of the nude mice treated with cisplatin were higher than those of the other groups. In nude mice pretreated with autophagy inhibitor and then co-treatment with autophagy inhibitor and cisplatin, the number of PGCC in primary tumors was less and the recurrence rate was significantly lower than in other groups. Conclusions: The mechanism of dormant polyploid giant cancer cells formation is related to autophagy. Inhibition of autophagy can inhibit the formation of PGCC and thus prevent the recurrence of nasopharyngeal carcinoma.
Collapse
Affiliation(s)
- T Xia
- Department of Otorhinolaryngology Head and Neck Surgery, the Affiliated Hospital of Nantong University, Institute of Otorhinolaryngology Head and Neck Surgery, the Affiliated Hospital of Nantong University, Nantong 226001, China
| | - Y Ji
- Clinical College, Medical School of Nantong University, Nantong 226001, China
| | - Y N Lu
- Clinical College, Medical School of Nantong University, Nantong 226001, China
| | - H J Xie
- Department of Otorhinolaryngology Head and Neck Surgery, the Affiliated Hospital of Nantong University, Institute of Otorhinolaryngology Head and Neck Surgery, the Affiliated Hospital of Nantong University, Nantong 226001, China
| | - Y W You
- Department of Otorhinolaryngology Head and Neck Surgery, the Affiliated Hospital of Nantong University, Institute of Otorhinolaryngology Head and Neck Surgery, the Affiliated Hospital of Nantong University, Nantong 226001, China
| | - B You
- Department of Otorhinolaryngology Head and Neck Surgery, the Affiliated Hospital of Nantong University, Institute of Otorhinolaryngology Head and Neck Surgery, the Affiliated Hospital of Nantong University, Nantong 226001, China
| |
Collapse
|
8
|
Xie HJ, Bae HJ, Noh JH, Eun JW, Kim JK, Jung KH, Ryu JC, Ahn YM, Kim SY, Lee SH, Yoo NJ, Lee JY, Park WS, Nam SW. Mutational analysis of JAK1 gene in human hepatocellular carcinoma. Neoplasma 2009; 56:136-40. [PMID: 19239328 DOI: 10.4149/neo_2009_02_136] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
UNLABELLED The <em>Janus kinase 1</em> (JAK1) gene encodes a cytoplasmic tyrosine kinase that is noncovalently associated with a variety of cytokine receptors and plays a nonredundant role in cell proliferation, survival, and differentiation. The mutated forms of JAK1 often altered the activation of JAK1 and then changed the activation of JAK1/STAT pathways, and this may contribute to cancer development and progression. Thus, to investigate whether genetic mutations of JAK1 gene are associated in hepatocellular carcinoma (HCC) progression, we analyzed genetic alterations of JAK1 gene in 84 human HCCs by single-strand conformational polymorphism (SSCP) and direct sequencing. Of 24 exons of JAK1 gene, 12 exons were previously reported to have mutations, we searched genetic alteration of JAK1 in these exons. Overall, one missense mutation (1.2%) was found. In addition, 12 cases (14%) were found to have single nucleotide polymorphism (14%) in exon 14. Taken together, we found one novel missense mutation of JAK1 gene in hepatocellular carcinomas with some polymorphisms. Although the functional assessment of this novel mutant remains to be completed, JAK1 mutation may contribute to the tumor development in liver cancer. KEYWORDS JAK1 gene, hepatocellular carcinoma, mutation.
Collapse
Affiliation(s)
- H J Xie
- Department of Pathology, Microdisection Genomic Research Center, College of Medicine, The Catholic University of Korea, Seoul, Korea
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|